Business Context and Reporting Period
This Form 8-K was filed by MEDICINOVA INC on August 4, 2023. The report discloses a corporate governance event involving the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the appointment of Nicole Lemerond as a member of the Board of Directors, effective immediately, to fill an existing vacancy. Key details include:
- Role: Class I Director (term expires at the 2026 Annual Meeting).
- Committee Assignments: Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.
- Background: Over 25 years of experience in investment management, private equity, and healthcare, formerly Managing Partner of NV Capital.
Compensation and Governance
Ms. Lemerond's compensatory arrangements include:
- Cash Retainer: A pro rata portion of the annual non-employee director retainer, paid quarterly.
- Stock Options: An option to purchase 18,333 shares of common stock.
- Vesting Schedule: Options vest in equal installments on September 30, 2023; December 31, 2023; March 31, 2024; and June 30, 2024, subject to continued service.
- Indemnification: Ms. Lemerond will enter into the Company's standard form of indemnification agreement.
Investor Verification Checklist
- Verify the total number of outstanding stock options granted to Ms. Lemerond (18,333 shares) and the specific vesting dates.
- Confirm the current composition of the Audit, Compensation, and Nominating committees following this appointment.
- Review the Company's non-employee director compensation policy to understand the pro rata retainer calculation.
- Check for any subsequent filings regarding Ms. Lemerond's continued service or changes to her committee assignments.